###begin article-title 0
A Novel Tandem Mass Spectrometry Method for Rapid Confirmation of Medium- and Very Long-Chain acyl-CoA Dehydrogenase Deficiency in Newborns
###end article-title 0
###begin p 1
Conceived and designed the experiments: FtV. Performed the experiments: FtV MM SK UH DH MDL SP. Analyzed the data: FtV MM DH MDL SP. Contributed reagents/materials/analysis tools: FtV MM MDL SP. Wrote the paper: FtV. Critical revision of the manuscript: DH EM US. Study concept and design and study supervision: US.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 615 620 <span type="species:ncbi:9606">human</span>
Newborn screening for medium- and very long-chain acyl-CoA dehydrogenase (MCAD and VLCAD, respectively) deficiency, using acylcarnitine profiling with tandem mass spectrometry, has increased the number of patients with fatty acid oxidation disorders due to the identification of additional milder, and so far silent, phenotypes. However, especially for VLCADD, the acylcarnitine profile can not constitute the sole parameter in order to reliably confirm disease. Therefore, we developed a new liquid chromatography tandem mass spectrometry (LC-MS/MS) method to rapidly determine both MCAD- and/or VLCAD-activity in human lymphocytes in order to confirm diagnosis.
###end p 3
###begin title 4
Methodology
###end title 4
###begin p 5
###xml 102 107 <span type="species:ncbi:9606">human</span>
LC-MS/MS was used to measure MCAD- or VLCAD-catalyzed production of enoyl-CoA and hydroxyacyl-CoA, in human lymphocytes.
###end p 5
###begin title 6
Principal Findings
###end title 6
###begin p 7
###xml 187 193 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
VLCAD activity in controls was 6.95+/-0.42 mU/mg (range 1.95 to 11.91 mU/mg). Residual VLCAD activity of 4 patients with confirmed VLCAD-deficiency was between 0.3 and 1.1%. Heterozygous ACADVL mutation carriers showed residual VLCAD activities of 23.7 to 54.2%. MCAD activity in controls was 2.38+/-0.18 mU/mg. In total, 28 patients with suspected MCAD-deficiency were assayed. Nearly all patients with residual MCAD activities below 2.5% were homozygous 985A>G carriers. MCAD-deficient patients with one other than the 985A>G mutation had higher MCAD residual activities, ranging from 5.7 to 13.9%. All patients with the 199T>C mutation had residual activities above 10%.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 144 149 <span type="species:ncbi:9606">human</span>
Our newly developed LC-MS/MS method is able to provide ample sensitivity to correctly and rapidly determine MCAD and VLCAD residual activity in human lymphocytes. Importantly, based on measured MCAD residual activities in correlation with genotype, new insights were obtained on the expected clinical phenotype.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Wanders1">[1]</xref>
###xml 648 651 648 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Arnold1">[2]</xref>
###xml 653 656 653 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Spiekerkoetter1">[3]</xref>
If undiagnosed and untreated, fatty acid oxidation defects (FAOD), such as medium- and very long-chain acyl-CoA dehydrogenase deficiency (MCADD and VLCADD, respectively), are associated with high morbidity and mortality [1]. Clinical presentation of VLCADD may include cardiomyopathy, metabolic encephalopathy, hypoglycaemia and rhabdomyolysis. MCADD is associated with hepatic symptoms that are predominantly related to intercurrent illnesses or prolonged fasting. Thus, early detection by newborn screening (NBS) is absolutely essential for achieving a more favourable outcome and indeed, disease mortality and morbidity is significantly reduced [2], [3].
###end p 11
###begin p 12
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 335 338 335 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Schulze1">[4]</xref>
###xml 533 536 533 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Schymik1">[5]</xref>
###xml 666 669 666 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Browning1">[6]</xref>
###xml 1171 1177 1171 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1177 1180 1177 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Leonard1">[7]</xref>
###xml 1232 1235 1232 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Arnold2">[8]</xref>
###xml 454 462 <span type="species:ncbi:9606">children</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
###xml 1097 1105 <span type="species:ncbi:9606">patients</span>
###xml 1348 1353 <span type="species:ncbi:8895">swift</span>
However, NBS for MCADD and VLCADD using tandem mass spectrometry screening identifies false-positive cases and the outcome of the expanded NBS program in Germany, including MCADD and VLCADD, was recently assessed by Schulze et al. demonstrating that the positive predictive values for MCADD and VLCADD were 25.8 and 3.1%, respectively [4]. In contrast to medium-chain acylcarnitines, mild accumulation of long-chain acylcarnitines is observed in healthy children due to activated mitochondrial fatty acid oxidation during catabolism [5]. Furthermore, VLCADD patients may well present with normal confirmatory secondary screening after day 3 of life during anabolism [6]. Taken together, each newborn with an acylcarnitine profile suggestive of MCADD or VLCADD needs further confirmatory diagnosis. Genotyping for prevalent mutations, i.e. the 985A>G mutation in case of MCADD, may represent rapid and cost-effective confirmatory techniques. However, the use of extended, and thus both time-consuming and expensive, mutation screening was reported to be necessary, particularly for suspected MCADD patients who are not of European descent, as recently reviewed by Leonard et al.[7]. Likewise, great molecular heterogeneity in VLCADD [8] makes extended mutation screening obligatory in most cases. Genotyping does, therefore, not always constitute a swift and cost-effective confirmatory diagnostic technique for a suspected FAOD in all cases.
###end p 12
###begin p 13
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
In this paper we present a novel, cost-effective and rapid method for the measurement of MCAD and VLCAD activity in human lymphocytes to correctly identify patients and to confirm disease. In addition, we correlate residual MCAD activities with genotype in MCADD.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 15
###begin p 16
Whole blood specimens were obtained from subjects with biochemical indication of MCADD or VLCADD, as identified in NBS, their parents and siblings. As the determination of MCAD and/or VLCAD residual activity constitutes a routine procedure performed by our laboratory, not being part of a scientific study in any way or form, informed consent from subjects, or their parents, was obtained by the referring physicians in oral fashion. The study was performed according to the rules of the Declaration of Helsinki and approved under study number 3230 by the ethical review board of Heinrich-Heine-University Dusseldorf.
###end p 16
###begin title 17
Reagents
###end title 17
###begin p 18
###xml 138 139 138 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Palmitoleoyl-CoA (C16:1-CoA), palmitoyl-CoA (C16:0-CoA) and octanoyl-CoA (C8:0-CoA) were purchased from Sigma (Deisenhofen, Germany) as Li+ salts and stored at -20degreesC. Ferrocenium hexafluorophosphate was obtained from Sigma-Aldrich (Deisenhofen, Germany).
###end p 18
###begin title 19
Procedures
###end title 19
###begin title 20
Isolation of lymphocytes from blood samples
###end title 20
###begin p 21
###xml 161 164 150 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Liebig1">[9]</xref>
Lymphocytes were isolated from 2 mL of whole blood using Ficoll-Paquetrade mark Plus (Amersham) and Leucosep (R) (Greiner Bio One) tubes as described previously [9].
###end p 21
###begin title 22
VLCAD and MCAD enzyme assay conditions
###end title 22
###begin p 23
###xml 113 114 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 213 215 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
Lymphocytes were resuspended in medium (200 microM ferrocenium hexafluorophosphate in 100 mM Tris-HCl or 10 mM NH4Ac for HPLC and LC-MS/MS analysis, respectively) to a final protein concentration of 30 microg . mL-1. Duplicate enzyme reactions for 5 min. at 37degreesC and pH = 8.0 were started by adding 4 microL of 5 mM C16:0-CoA as substrate to a total reaction volume of 100 microL. For HPLC analysis, quenching was achieved by adding 10 microL of 2 M HCl, followed by 5 min. of incubation on ice and neutralization with 2 M KOH. For LC-MS/MS analysis, the reaction was quenched by adding 100 microL of -20degreesC acetonitrile. Subsequently, proteins were removed by precipitation at 13000 rpm for 5 min. and by filtering the supernatant through 96-well 1.2 microm filter plates (Millipore, Schwalbach, Germany). C16:0-CoA was replaced by C8:0-CoA in the MCAD assay, at a concentration of 5 mM.
###end p 23
###begin title 24
High-pressure-liquid-chromatography analysis
###end title 24
###begin p 25
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Woldegiorgis1">[10]</xref>
###xml 328 329 324 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 331 332 327 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 370 371 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 373 374 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 437 438 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 440 441 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 516 517 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 519 520 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 595 596 591 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 598 599 594 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 681 682 677 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 684 685 680 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
VLCAD assay products, C16:1-CoA and C16:OH-CoA, and the C16:0-CoA substrate were measured based on a method published by Woldegiorgis et al. [10]. Briefly, a Phenomenex C18(2) Luna column (250 mmx4.6 mmx5 microm) in combination with a C18 Luna guard column were used. The two mobile-phase solvents were acetonitrile and 25 mM KH2PO4, pH = 6.9. Following 2 min. of 70% KH2PO4 and 30 5 ACN, a three-step linear gradient was used; 1) 70% KH2PO4 reduced to 60% and 30% acetonitrile increased to 40% over 5 min. 2) 60% KH2PO4 reduced to 54% and 40% acetonitrile increased to 46% over 9 min. 3) 54% KH2PO4 reduced to 38% and 46% acetonitrile increased to 62% over 5 min. Next, the 38% KH2PO4/62% acetronitrile mixture was run for 5 min. Finally, the system was equilibrated for 5 min. The injection volume was 10 microL at a flow rate of 1.5 mL/min. The acyl-CoA esters were detected at 254 nm and 16:1-CoA, C16:OH-CoA and C16:0-CoA eluted at 11,6; 16,6 and 17,5 min, respectively. Quantitation was based on peak areas, with the initial substrate C16:0-CoA amount set to 20 nmol.
###end p 25
###begin title 26
Tandem mass spectrometry analysis
###end title 26
###begin p 27
###xml 558 559 544 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 747 748 729 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
In quenched VLCAD and MCAD assay samples, C16:1-CoA; C16:OH-CoA; C16:0-CoA and C8:1-CoA; C8:OH-CoA; C8:0-CoA, respectively, were quantified by LC-MS/MS. A Waters 2795 Alliance HPLC system (Waters, Milford, UK), equipped with a thermostated autosampler, was used for solvent delivery and sample introduction. Assay samples were placed in a cooled sample tray (15degreesC) and 5 microL was injected onto a C18(2) Phenomenex Luna column (100x2.0 mmx3 microm). C16:OH-CoA, C16:1-CoA and C16:0-CoA were eluted isocratically with 55% (v/v) acetonitrile in 10 mM NH4Ac (pH was not adjusted and was approx. 6.7) at a flow rate of 200 microL/min. Similarly, C8:OH-CoA, C8:1-CoA and C8:0-CoA were eluted isocratically with 30% (v/v) acetonitrile in 10 mM NH4Ac. The eluate was delivered into a Quattro Micro MS/MS (Micromass, Cambridge, UK) with an ESI probe in positive ion mode. Injection interval was 5 min. Nitrogen was used as drying gas at 650 L/h. Collision energy was 35 eV and argon was used as collision gas. Declustering potential was 45 V and ion source temperature was 100degreesC. Compounds were detected in the multiple reaction monitoring (MRM) mode with the following mass transitions for the VLCAD assay: C16:OH-CoA, m/z 1022.4 --> 515.2, C16:1-CoA, m/z 1004.4 --> 497.2 and C16:0-CoA, m/z 1006.4 --> 499.2, respectively, and C8:OH-CoA, m/z 910.4 --> 403.2, C8:1-CoA, m/z 892.4 --> 385.3 and C8:0-CoA, m/z 894.4 --> 387.2, respectively, for the MCAD assay.
###end p 27
###begin p 28
Quantitation was based on peak area ratios, with the initial substrate C16:0-CoA or C8:0-CoA amount set to 20 nmol.
###end p 28
###begin title 29
Identification of mutations in the ACADM and ACADVL gene
###end title 29
###begin p 30
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
###xml 236 240 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen1">[11]</xref>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 318 321 318 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Liebig1">[9]</xref>
Genomic DNA from whole blood was isolated using DNA Mini kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) was used to amplify all twelve ACADM exons, including part of the flanking intron sequences as previously described [11]. ACADVL, containing 20 exons, was analyzed according to Spiekerkoetter et al.[9]. The amplified DNA fragments were separated by electrophoresis and extracted (QIAquick Gel Extraction kit, Quiagen). PCR products were subjected to DNA sequence analysis using the Cycle sequencing kit, (Applied Biosystems, Weiterstadt, Germany). Analysis was performed using an Applied Biosystems Prism 310 Genetic Analyser.
###end p 30
###begin title 31
Statistical methods
###end title 31
###begin p 32
###xml 265 266 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Data were acquired and analysed using MassLynx NT v4.0 (Micromass, UK). Reported data are presented as means+/-standard error of the mean (s.e.m.). Statistical analyses were performed using Student's t-test. Differences between means were considered significant if p<0.05.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Characterization and validation of the acyl-CoA dehydrogenase assays
###end title 34
###begin p 35
###xml 83 91 83 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g001">Figure 1</xref>
###xml 216 231 210 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g001">Fig. 1, A and B</xref>
###xml 280 295 268 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g001">Fig. 1, C and D</xref>
###xml 694 697 678 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 890 897 874 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vivo</italic>
###xml 897 901 881 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Powell1">[12]</xref>
###xml 903 907 887 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Davidson1">[13]</xref>
Representative VLCAD assay multiple reactant monitoring chromatograms are shown in Figure 1. The sample was either quenched instantly by adding -20degreesC acetonitrile, subsequent to substrate (C16:0-CoA) addition (Fig. 1, A and B), or was incubated for 5 minutes at 37degreesC (Fig. 1, C and D). The hydroxyl-CoA product eluted first (C16:OH-CoA fragment ion, m/z 1022.4 --> 515.2) at 1.9 min. and the enoyl-CoA peak (C16:1-CoA fragment ion, m/z 1004.4 --> 497.2) eluted at 3.2 min. The observed C16:1-CoA peak eluting at 4.0 min. was independent of assay incubation time or sample amount and was solely dependent on palmitoyl-CoA substrate concentration, most likely identifying it as C16:1-cis-9-CoA impurity in the commercial palmitoyl-CoA preparation. As enoyl-CoA products are rapidly converted into hydroxyacyl-CoA by matrix 2-enoyl-hydratases, in order to avoid product inhibition in-vivo[12], [13], it was critical to include hydroxyacyl-CoA as acyl-CoA dehydrogenase product to avoid underestimation of catalytic turnover.
###end p 35
###begin title 36
Multiple Reactant Monitoring (MRM) chromatograms of quenched VLCAD assay samples.
###end title 36
###begin p 37
C16:OH-CoA, m/z 1022.4 --> 515.2 (A and B) and C16:1-CoA, m/z 1004.4 --> 497.2 (C and D) after 0 (A and C) and 5 (B and D) min. of incubation.
###end p 37
###begin p 38
The oxidation products in the MCAD assay, C8:OH-CoA and C8:1-CoA, and the added substrate C8:0-CoA had fragment masses of m/z 910.4 --> 403.2, 892.4 --> 385.3 and 894.4 --> 387.2, respectively. MCAD and VLCAD activities in lymphocytes were linear up to 20 min, proportional to the amount of protein added in the range of 10 to 50 microg and were independent of ferrocenium hexafluorophosphate electron acceptor concentrations above 50 microM.
###end p 38
###begin p 39
The inter-assay variation (CV) for the HPLC and LC-MS/MS method were determined by measuring the VLCAD activity in the same control lymphocytes on 8 different days and were 9% and 13%, respectively. To determine the intra-assay variation (CV), VLCAD activity was measured in one control lymphocyte sample in triplicate on two consecutive days. Intra-assay variations were 3% and 4% for the HPLC and LC-MS/MS method, respectively.
###end p 39
###begin p 40
###xml 239 245 239 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Fig. 2</xref>
###xml 373 375 373 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">yx</sub>
###xml 389 395 387 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Fig. 2</xref>
###xml 163 168 <span type="species:ncbi:9606">human</span>
We compared results obtained with our newly developed LC-MS/MS VLCAD assay with VLCAD activities determined by HPLC. In a direct comparison of VLCAD activities in human lymphocytes, the LC-MS/MS method correlates well with the HPLC assay (Fig. 2). We observed that correlation between the established HPLC and newly developed LC-MS/MS method was excellent (r = 0.941) and Syx was+/-0.804 (Fig. 2).
###end p 40
###begin title 41
Comparison of results of the standard HPLC assay and the LC-MS/MS assay from the same lymphocyte sample.
###end title 41
###begin p 42
###xml 101 107 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 152 158 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
Total number of subjects tested was 52. (*) Normal controls. (black triangle) Confirmed heterozygous ACADVL mutation carriers. (o) Confirmed homozygous ACADVL mutation carriers.
###end p 42
###begin title 43
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Determination of residual VLCAD activities in patients
###end title 43
###begin p 44
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 163 169 163 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Fig. 2</xref>
###xml 301 303 301 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 316 318 316 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 368 370 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 383 385 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 387 393 383 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Fig. 2</xref>
###xml 490 496 486 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 533 535 527 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 548 550 542 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 617 619 611 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 632 634 626 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 636 642 630 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Fig. 2</xref>
###xml 686 692 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 762 764 756 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 777 779 771 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 863 869 857 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 958 960 950 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 973 975 965 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 977 983 969 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Fig. 2</xref>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
In total, 52 subjects were measured with our LC-MS/MS VLCAD assay. Four were identified as VLCADD patients and 9 were heterozygous carriers of an ACADVL mutation (Fig. 2). VLCAD activities measured by LC-MS/MS in the samples collected from normal subjects (n = 36) ranged from 1.95 to 11.91 nmol . min-1 . mg protein-1, with a mean+/-SE value of 6.95+/-0.42 nmol . min-1 . mg protein-1 (Fig. 2). Average residual VLCAD activities of four confirmed patients, being homozygous carriers of an ACADVL mutation, was 0.13+/-0.07 nmol . min-1 . mg protein-1, representing residual activities between 0.02 and 0.34 nmol . min-1 . mg protein-1 (Fig. 2). In confirmed heterozygous carriers of an ACADVL mutation, residual VLCAD activity ranged from 1.07 to 3.77 nmol . min-1 . mg protein-1. VLCAD activity measurements with HPLC revealed comparable results, but homozygous ACADVL mutation carriers had a higher average residual VLCAD activity of 0.55+/-0.01 nmol . min-1 . mg protein-1 (Fig. 2).
###end p 44
###begin title 45
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Determination of residual MCAD activities in patients
###end title 45
###begin p 46
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 141 143 141 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 193 195 189 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 208 210 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 212 219 208 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 749 756 745 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 560 568 <span type="species:ncbi:9606">Patients</span>
MCAD activities measured by LC-MS/MS in the samples collected from normal subjects (n = 6) ranged from 1.82 to 2.78 nmol . min-1 . mg protein-1, with a mean+/-SE value of 2.38+/-0.18 nmol . min-1 . mg protein-1. Table 1 lists 28 examined cases that were assayed for MCAD activity, parents of newborns are highlighted. With the exception of cases 4, 6 and 8 all patients with residual MCAD activities below 2.5% were homozygous carriers of the 985A>G mutation. MCADD patients with other mutations had higher MCAD residual activities, ranging from 5.7 to 13.9%. Patients carrying one 199T>C mutation presented with residual activities above 10%. Confirmed 985A>G heterozygotes (cases 20, 22 and 23) had residual MCAD activities above 24% of controls (Table 1).
###end p 46
###begin title 47
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
Octanoyl-CoA oxidation, plasma medium-chain acylcarnitine levels and gene analysis of both ACADM alleles in subjects with suspected MCAD-deficiency.
###end title 47
###begin p 48
Case 1 to 18 were identified in NBS, with the exception of 4 and 8.
###end p 48
###begin p 49
###xml 135 137 135 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 142 144 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
Relative residual MCAD enzyme activities are presented as a percentage of the mean of lymphocytes from healthy control (2.38 nmol . min-1 . mg-1, n = 6).
###end p 49
###begin p 50
###xml 136 138 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
First octanoylcarnitine specimen (C8:0 I) obtained on day 2-5 of life and subsequent repeat specimen (C8:0 II) are shown in micromol . L-1, cut-off was set at 0.30.
###end p 50
###begin p 51
Parents of 12.
###end p 51
###begin p 52
Parents of 16.
###end p 52
###begin p 53
Intervening sequences: IVS2-32C>G, IVS3+10T>C, IVS5+32C>G, IVS7-22C>A.
###end p 53
###begin p 54
Intervening sequences: IVS2-32C>G, IVS3+10T>C, IVS5+32C>G, IVS6-14A>G and IVS7-22C>A.
###end p 54
###begin p 55
subjects with clinical suspicion of MCADD.
###end p 55
###begin title 56
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Genotypes of MCAD-deficient patients
###end title 56
###begin p 57
###xml 78 85 78 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Maier1">[15]</xref>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen2">[16]</xref>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 698 702 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen2">[16]</xref>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen1">[11]</xref>
###xml 806 810 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 1021 1026 1021 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
###xml 1363 1370 1363 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Mutation analysis revealed that 8 out of 18 patients were 985A>G homozygotes (Table 1). Cases 4 and 8 presented with an insertion at position 245, as reported previously by Gregersen et al. and Maier et al.[14], [15], and were heterozygous for a splicing mutation (IVS9+2T>C). In addition, multiple other intronic sequence variants (IVS) were observed (IVS2-32C>G, IVS3+10T>C, IVS5+32C>G, IVS7-22C>A). Case 6, in addition to mutation 985A>G, carried the 347G>A mutation, a mutation previously described as severe [14], [16]. To the best of our knowledge, case 14 carried a novel mutation and was homozygous for 823A>G. Case 15 was a homozygous carrier of the 157C>T mutation, reported earlier [14]-[16]. Cases 16 and 17 were compound heterozygous for mutations 985A>G and 199T>C, as reported earlier [11], [14]. An insertion at position 1140 was identified in case 18 and was also previously not reported. In cases 18, 24, 26-28 a FAOD was clinically suspected but the subjects turned out not to carry a mutation on both ACADM alleles. Case 21, parent of case 12, had multiple heterozygous intervening sequences (IVS2-32C>G, IVS3+10T>C, IVS5+32C>G, IVS6-14A>G and IVS7-22C>A). Cases 12 and 13 originated from different families and were both heterozygous carriers of the same above described intervening sequences, in addition to their classical 985A>G mutation (Table 1).
###end p 57
###begin title 58
Correlation of genotype with MCAD residual activity and C8:0-carnitine concentration
###end title 58
###begin p 59
###xml 16 23 16 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 289 295 285 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g003">Fig. 3</xref>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
As indicated in Table 1, initial C8:0-carnitine does not always correlate with genotype and residual enzyme activity. However, a high C8:0-carnitine above >10 microM was only observed in MCADD patients with residual MCAD activities below 2% of controls and the homozygous 985A>G mutation (Fig. 3).
###end p 59
###begin title 60
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Plasma octanoyl-carnitine (C8:0) concentrations determined in dried blood spots during initial newborn screening and subsequent follow-up from patients carrying two confirmed ACADM mutations.
###end title 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 368 376 <span type="species:ncbi:9606">children</span>
Our newly developed tandem MS method for the determination of MCAD- and VLCAD-enzyme activities in human lymphocytes is able to provide ample sensitivity to correctly and rapidly confirm diagnosis of the respective disorder in individuals identified by newborn screening. This technique is of great importance because long-chain acylcarnitines are elevated in healthy children or VLCAD heterozygotes, due to activated fatty acid oxidation in the first 2-3 days of life, and are thus interfering with NBS results. In case of MCADD, this assay also offers the possibility to predict severity of expected clinical phenotype based on residual MCAD activities and correlating genotype.
###end p 62
###begin p 63
As the LC-MS/MS analytical apparatus is available in all NBS laboratories worldwide, it was important to develop an analysis method that can be used with available NBS instruments. This newly developed method thus offers the possibility to determine MCAD or VLCAD activity in one single setup, without exchanging columns, and lacking complex gradients.
###end p 63
###begin title 64
###xml 34 41 <span type="species:ncbi:9606">patient</span>
Residual VLCAD activity in VLCADD patient lymphocytes
###end title 64
###begin p 65
###xml 97 99 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 112 114 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 200 204 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Wanders2">[17]</xref>
###xml 205 209 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Voermans1">[19]</xref>
###xml 211 219 209 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g002">Figure 2</xref>
###xml 404 410 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
Enzyme activities of VLCAD in human lymphocytes from healthy controls were 6.95+/-0.42 nmol . min-1 . mg protein-1 (n = 36) and are similar to control values reported previously by other laboratories [17]-[19]. Figure 2 clearly shows that heterozygous carriers can not be discriminated from healthy controls in all cases. However, most importantly, VLCADD patients confirmed by molecular analysis of the ACADVL gene can unequivocally be identified based on the determination of residual VLCAD activity in isolated lymphocytes.
###end p 65
###begin title 66
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
Correlation of residual MCAD activity with ACADM genotype
###end title 66
###begin p 67
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
###xml 422 428 422 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
###xml 538 544 538 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADVL</italic>
Unlike VLCADD with molecular heterogeneity, MCAD-deficiency possesses the prevalent 985A>G mutation and, since NBS, the less common 199T>C mutation. The total number of individual ACADM mutations reported so far is approx. 25, as reviewed in [14]. We therefore, attempted to correlate residual MCAD-activities with our ACADM genotyping results. This was not pursued for VLCAD activities and corresponding mutations in the ACADVL gene, also because of much greater molecular heterogeneity and due the limited number of observed homozygous ACADVL mutation carriers.
###end p 67
###begin p 68
###xml 63 65 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 78 80 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 131 135 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Wanders2">[17]</xref>
###xml 137 141 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-NiezenKoning1">[20]</xref>
###xml 143 147 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Duran1">[21]</xref>
###xml 314 321 312 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 558 562 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen1">[11]</xref>
###xml 564 568 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen2">[16]</xref>
###xml 710 714 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen2">[16]</xref>
###xml 844 848 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 850 854 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen2">[16]</xref>
###xml 968 972 966 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 1108 1112 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 1553 1557 1551 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 1766 1770 1764 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-N1">[14]</xref>
###xml 1771 1775 1769 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Andresen2">[16]</xref>
###xml 2015 2020 2013 2018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACADM</italic>
###xml 2280 2287 2278 2285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006449-t001">Table 1</xref>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 758 765 <span type="species:ncbi:9606">patient</span>
###xml 1015 1023 <span type="species:ncbi:9606">children</span>
###xml 1319 1327 <span type="species:ncbi:9606">patients</span>
###xml 1572 1580 <span type="species:ncbi:9606">patients</span>
MCAD activities in healthy controls were 2.38+/-0.18 nmol . min-1 . mg protein-1, (n = 6) being in agreement with previous reports [17], [20], [21]. The MCAD assay was applied in lymphocyte samples from 28 subjects with suspected MCAD-deficiency. In 18 individuals, diagnosis was confirmed by mutational analysis (Table 1). All patients with the homozygous, classical 985A>G mutation had residual MCAD activities below 2.5%, therefore well in line with previous reports that identify the homozygous status of the 985A>G mutation as severe clinical phenotype [11], [16]. The 985A>G mutation was the prevalent MCAD mutation before the NBS era and patients were identified because of hypoglycaemia or hepatopathy [16]. In addition to mutation 985A>G, one MCADD patient was carrier of the 347G>A mutation, a mutation previously described as severe [14], [16], this again is in excellent agreement with a low residual MCAD activity of 1.1%. The more recent 199T>C mutation [14] was identified in a significant number of children since implementation of NBS and is considered to induce a much milder MCADD variant [14]. In our cohort, this mutation was identified three times, two in combination with the 985A>G mutation, and all three resulted in significantly higher residual MCAD activities of approx. 11%, as compared to patients being homozygous for the 985A>G mutation. Also demonstrating that MCADD severity, in case of compound heterozygosity, is determined by the mutation that is known to be the mildest of the two, in this case the 199T>C mutation [14]. In addition, patients with a heterozygous 245insT mutation and a second splicing IVS9+2T>C mutation had comparably lower residual activities of <2.5%. For the homozygous 157C>T mutation, reported earlier by [14]-[16] to result in a mild clinical phenotype, enzymatic analysis now revealed that this mutation leads to 9.3% residual MCAD activity. Interestingly, two unrelated cases presented with the 985A>G mutation plus identical mutations in intervening ACADM sequences (IVS2-32C>G, IVS3+10T>C, IVS5+32C>G, IVS6-14A>G and IVS7-22C>A) and both had residual MCAD activities of 6%. Heterozygous carriers of the 985A>G mutation without a second mutation (cases 20, 22 and 23) had residual MCAD activities of 24% or higher (Table 1).
###end p 68
###begin title 69
The use of plasma octanoyl-carnitine levels in newborn screening for MCADD
###end title 69
###begin p 70
###xml 182 188 182 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006449-g003">Fig. 3</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006449-Chace1">[22]</xref>
In our hands, measured plasma octanoyl-carnitine (C8:0) levels, based on the initial newborn screening dried blood spot, indeed functions as sensitive and specific marker for MCADD (Fig. 3). However, the C8:0-carnitine values measured are unable to discriminate between MCADD of different severity. This also applies to the repeat specimen upon confirmatory second screening, being well in line with a previous report from Chace and co-workers [22].
###end p 70
###begin title 71
Possible limitations of this study
###end title 71
###begin p 72
###xml 316 324 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 374 381 374 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vivo</italic>
The use of isolated peripheral blood lymphocytes may well not be fully representative for all individual organs that are differentially afflicted by MCADD or VLCADD. Of note, studies in fibroblasts would obviously present similar limitations. Furthermore, the use of ferrocenium as artificial oxidizing agent in our in-vitro assay, instead of electron transfer flavoprotein in-vivo, may possibly obscure alterations in MCAD and VLCAD activity induced by mutations that impair flavin adenine dinucleotide binding and/or electron transfer flavoprotein interaction.
###end p 72
###begin title 73
Conclusions
###end title 73
###begin p 74
###xml 129 134 <span type="species:ncbi:9606">human</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
Taken together, we have developed a new assay that allows fast and reliable determination of MCAD and VLCAD residual activity in human lymphocytes. This method takes advantage of LC-MS/MS detection and can be implemented in any NBS laboratory using LC-MS/MS technique. Both methods provide reference values for MCAD and VLCAD enzyme activity in lymphocytes from healthy controls that correspond well with published rates in literature. Importantly, both methods provide ample sensitivity to discriminate not only patients from healthy individuals but, in case of MCADD, this method also offers the possibility to differentiate between clinical phenotypes of different severity based on residual MCAD activities, in line with their genotype.
###end p 74
###begin title 75
References
###end title 75
###begin article-title 76
Disorders of mitochondrial fatty acyl-CoA beta-oxidation.
###end article-title 76
###begin article-title 77
A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.
###end article-title 77
###begin article-title 78
Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop.
###end article-title 78
###begin article-title 79
Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications.
###end article-title 79
###begin article-title 80
Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
###end article-title 80
###begin article-title 81
Normal acylcarnitine levels during confirmation of abnormal newborn screening in long-chain fatty acid oxidation defects.
###end article-title 81
###begin article-title 82
Newborn screening for medium chain acyl CoA dehydrogenase deficiency.
###end article-title 82
###begin article-title 83
A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.
###end article-title 83
###begin article-title 84
Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels.
###end article-title 84
###begin article-title 85
Extraction of tissue long-chain acyl-CoA esters and measurement by reverse-phase high-performance liquid chromatography.
###end article-title 85
###begin article-title 86
###xml 102 110 <span type="species:ncbi:9606">patients</span>
The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype?
###end article-title 86
###begin article-title 87
###xml 61 64 <span type="species:ncbi:9823">pig</span>
Interaction of acyl coenzyme A substrates and analogues with pig kidney medium-chain acyl-coA dehydrogenase.
###end article-title 87
###begin article-title 88
###xml 78 84 <span type="species:ncbi:9913">bovine</span>
Separation, properties, and regulation of acyl coenzyme A dehydrogenases from bovine heat and liver.
###end article-title 88
###begin article-title 89
Mitochondrial fatty acid oxidation defects-remaining challenges.
###end article-title 89
###begin article-title 90
Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency.
###end article-title 90
###begin article-title 91
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency.
###end article-title 91
###begin article-title 92
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Fatty acid beta-oxidation in leukocytes from control subjects and medium-chain acyl-CoA dehydrogenase deficient patients.
###end article-title 92
###begin article-title 93
A newborn with VLCAD deficiency Clinical, biochemical, and histopathological findings.
###end article-title 93
###begin article-title 94
Rhabdomyolysis caused by an inherited metabolic disease: very long-chain acyl-CoA dehydrogenase deficiency.
###end article-title 94
###begin article-title 95
Determination of medium chain acyl-CoA dehydrogenase activity in cultured skin fibroblasts using mass spectrometry.
###end article-title 95
###begin article-title 96
Diagnosis of medium-chain acyl-CoA dehydrogenase deficiency in lymphocytes and liver by a gas chromatographic method: the effect of oral riboflavin supplementation.
###end article-title 96
###begin article-title 97
Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry.
###end article-title 97
###begin p 98
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 98
###begin p 99
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The study was financially supported by grants from the Forschungskommission of the medical Faculty of the Heinrich-Heine-University Duesseldorf and from the Deutsche Forschungsgemeinschaft (DFG, SP1125/1-1 and SFB 575 and 612). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 99

